Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 16 studies | 26% ± 8% | |
glutamatergic neuron | 6 studies | 41% ± 23% | |
oligodendrocyte | 6 studies | 24% ± 7% | |
natural killer cell | 5 studies | 18% ± 2% | |
epithelial cell | 5 studies | 34% ± 13% | |
endothelial cell of lymphatic vessel | 5 studies | 27% ± 7% | |
astrocyte | 5 studies | 29% ± 9% | |
oligodendrocyte precursor cell | 5 studies | 28% ± 11% | |
fibroblast | 5 studies | 19% ± 5% | |
macrophage | 5 studies | 26% ± 5% | |
B cell | 4 studies | 21% ± 4% | |
CD4-positive, alpha-beta T cell | 4 studies | 18% ± 2% | |
neuron | 4 studies | 27% ± 8% | |
microglial cell | 4 studies | 23% ± 4% | |
myeloid cell | 4 studies | 18% ± 3% | |
lymphocyte | 4 studies | 26% ± 8% | |
GABAergic neuron | 4 studies | 43% ± 15% | |
smooth muscle cell | 4 studies | 17% ± 2% | |
interneuron | 4 studies | 37% ± 21% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 18% ± 3% | |
ciliated cell | 3 studies | 24% ± 6% | |
dendritic cell | 3 studies | 27% ± 12% | |
monocyte | 3 studies | 20% ± 2% | |
pericyte | 3 studies | 21% ± 2% | |
goblet cell | 3 studies | 30% ± 16% | |
transit amplifying cell | 3 studies | 29% ± 19% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 7 studies | 36% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3455.30 | 1445 / 1445 | 100% | 29.18 | 183 / 183 |
uterus | 100% | 3545.48 | 170 / 170 | 100% | 17.64 | 459 / 459 |
breast | 100% | 3484.78 | 459 / 459 | 100% | 21.44 | 1117 / 1118 |
lung | 100% | 3897.81 | 578 / 578 | 100% | 16.63 | 1153 / 1155 |
intestine | 100% | 3379.37 | 966 / 966 | 100% | 14.77 | 526 / 527 |
brain | 100% | 2736.88 | 2636 / 2642 | 100% | 22.41 | 705 / 705 |
prostate | 100% | 2826.33 | 245 / 245 | 99% | 15.54 | 499 / 502 |
ovary | 100% | 3334.82 | 180 / 180 | 99% | 12.20 | 427 / 430 |
stomach | 100% | 2427.89 | 359 / 359 | 99% | 16.19 | 284 / 286 |
thymus | 100% | 3516.51 | 653 / 653 | 99% | 14.66 | 600 / 605 |
bladder | 100% | 3175.95 | 21 / 21 | 99% | 14.48 | 498 / 504 |
pancreas | 98% | 1279.39 | 323 / 328 | 99% | 15.23 | 177 / 178 |
kidney | 100% | 2569.98 | 89 / 89 | 96% | 13.90 | 868 / 901 |
skin | 100% | 3589.95 | 1809 / 1809 | 95% | 15.69 | 447 / 472 |
liver | 100% | 1471.22 | 226 / 226 | 94% | 7.39 | 381 / 406 |
adrenal gland | 100% | 2247.81 | 258 / 258 | 93% | 11.61 | 214 / 230 |
adipose | 100% | 3925.00 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3754.54 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 14.88 | 29 / 29 |
spleen | 100% | 3764.65 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 22.30 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.18 | 1 / 1 |
muscle | 100% | 2608.52 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2462.82 | 850 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 90% | 1847.51 | 834 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 86% | 8.06 | 69 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043029 | Biological process | T cell homeostasis |
GO_0048286 | Biological process | lung alveolus development |
GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0009791 | Biological process | post-embryonic development |
GO_0042098 | Biological process | T cell proliferation |
GO_0048535 | Biological process | lymph node development |
GO_0060173 | Biological process | limb development |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0035264 | Biological process | multicellular organism growth |
GO_0001782 | Biological process | B cell homeostasis |
GO_0050852 | Biological process | T cell receptor signaling pathway |
GO_0048536 | Biological process | spleen development |
GO_2000320 | Biological process | negative regulation of T-helper 17 cell differentiation |
GO_0061470 | Biological process | T follicular helper cell differentiation |
GO_2000628 | Biological process | regulation of miRNA metabolic process |
GO_0000288 | Biological process | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay |
GO_0016020 | Cellular component | membrane |
GO_0000932 | Cellular component | P-body |
GO_0009986 | Cellular component | cell surface |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0003677 | Molecular function | DNA binding |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0003729 | Molecular function | mRNA binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0003723 | Molecular function | RNA binding |
GO_0035613 | Molecular function | RNA stem-loop binding |
GO_0003725 | Molecular function | double-stranded RNA binding |
Gene name | RC3H2 |
Protein name | Ring finger and CCCH-type domains 2 RING-type E3 ubiquitin transferase (EC 2.3.2.27) Roquin-2 (EC 2.3.2.27) (Membrane-associated nucleic acid-binding protein) (RING finger and CCCH-type zinc finger domain-containing protein 2) (RING finger protein 164) (RING-type E3 ubiquitin transferase Roquin-2) |
Synonyms | MNAB RNF164 |
Description | FUNCTION: Post-transcriptional repressor of mRNAs containing a conserved stem loop motif, called constitutive decay element (CDE), which is often located in the 3'-UTR, as in HMGXB3, ICOS, IER3, NFKBID, NFKBIZ, PPP1R10, TNF and in many more mRNAs. Binds to CDE and promotes mRNA deadenylation and degradation. This process does not involve miRNAs. In follicular helper T (Tfh) cells, represses of ICOS and TNFRSF4 expression, thus preventing spontaneous Tfh cell differentiation, germinal center B-cell differentiation in the absence of immunization and autoimmunity. In resting or LPS-stimulated macrophages, controls inflammation by suppressing TNF expression. Also recognizes CDE in its own mRNA and in that of paralogous RC3H1, possibly leading to feedback loop regulation (By similarity). miRNA-binding protein that regulates microRNA homeostasis. Enhances DICER-mediated processing of pre-MIR146a but reduces mature MIR146a levels through an increase of 3' end uridylation. Both inhibits ICOS mRNA expression and they may act together to exert the suppression . Acts as a ubiquitin E3 ligase. Pairs with E2 enzymes UBE2B, UBE2D2, UBE2E2, UBE2E3, UBE2G2, UBE2K and UBE2Q2 and produces polyubiquitin chains . Shows the strongest activity when paired with UBE2N:UBE2V1 or UBE2N:UBE2V2 E2 complexes and generate both short and long polyubiquitin chains . Involved in the ubiquitination of MAP3K5 . Able to interact with double-stranded RNA (dsRNA) . . |
Accessions | H0Y5D9 Q4VXB2 ENST00000357244.7 [Q9HBD1-1] Q9HBD1 ENST00000498479.5 [Q9HBD1-2] A6NHN2 ENST00000373670.5 [Q9HBD1-1] ENST00000454740.5 ENST00000471874.2 [Q9HBD1-5] ENST00000398671.2 ENST00000335387.9 ENST00000423239.6 [Q9HBD1-4] |